About the Company
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on MYRIAD GENETICS INC
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 5, Daniel Brennan from ...
Myriad Genetics Inc. - The New York Times
He led Myriad Genetics, whose patents on the BRCA1 and BRCA2 genes, associated with breast cancer, were invalidated by the Supreme Court. By Neil Genzlinger Taking a DNA test for fun, then finding ...
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that ...
ANGLE Announces Collaboration with Myriad Genetics
Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20, ...
Myriad Genetics Inc. | BioWorld
BioWorld Content on 'Myriad Genetics Inc.'Makers of biotech therapies and in vitro diagnostics may be understandably weary of hearing about patent subject matter eligibility under Section 101 of the ...
Myriad Genetics, Inc.: New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer ...
Myriad Genetics (MYGN) To Share Guarded BRCA Variant ... - Forbes
Sep 21, 2020 South San Francisco / CA / USA - Myriad headquarters in Silicon Valley; Myriad Genetics, Inc. is an American molecular diagnostic company UNITED STATES - APRIL 15, 2013: Lisa Schlager ...
Myriad Genetics Stock: Do Not Expect Breakthroughs
Despite the industry growth, the stock of Myriad Genetics sputtered over the past 5 years (-23.4%). It slipped 12% over the past 12 months. 2023 has been a good year. The stock popped by +47.67%.
Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ETCompany ParticipantsMatt Scalo - Senior Vice President, ...
Myriad Genetics and Illumina Achieve Milestones in Strategic ...
--Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc., a global leader in DNA sequencing ...
Myriad Genetics Inc. - Page 4 - The New York Times
Myriad Genetics Inc to buy and sell option for 400,000 of its own shares, move it expects could make it up to $3 million if stock price rises more than 13 percent in next 14 months (S) ...
Angle announces collaboration with Myriad Genetics for molecular analysis
Angle announces collaboration with Myriad Genetics for molecular analysis: Guildford, Surrey Friday, August 22, 2025, 13:00 Hrs [IST] Angle plc, a world-leading liquid biopsy comp ...
Similar Companies
Loading the latest forecasts...